11:10 Fri 06 Dec 2019
Futura Medical PLC - Block Listing Six Monthly Return
Block Listing Six Monthly Return
Date:
|
|
|||
|
Unapproved Share Option Scheme Unapproved Share Incentive Scheme EMI Share Option Scheme |
|||
Period of return: |
From: |
|
To: |
|
Balance of unallotted securities under scheme(s) from previous return: |
6,225,000 |
|||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
n/a |
|||
Less: Number of securities issued/allotted under scheme(s) during period: |
n/a |
|||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
6,225,000 |
|||
Number and class of securities originally admitted and the date of admission |
USOS Total: 3,882,912 814,424 1,202,280 1,466,208 400,000
USIS Total: 425,000 425,000
EMI Total: 7,012,088 1,520,576 1,467,720 1,893,792 790,000 30 May 2018 1,340,000 |
|||
For further information please contact:
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
Nominated Adviser and Sole Broker:
Liberum
Bidhi Bhoma/
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Mary Clark/
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144
Notes to editors:
About
The first European Phase 3 study for MED2005, referred to as "FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study of MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment of erectile dysfunction with an open label extension. FM57 is progressing on track, with headline data expected by the end of 2019.
Futura is based in
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE